BIO Announces New Deputy General Counsel for Healthcare Regulatory Affairs
WASHINGTON, D.C. (January 9, 2007) -- The Biotechnology Industry Organization (BIO) is pleased to announce the recent hire of Sandra J. P. Dennis as BIO’s new Deputy General Counsel for Healthcare Regulatory Affairs.
“Ms. Dennis is a great addition to our world-class advocacy team,” stated BIO President and CEO Jim Greenwood. “She brings to BIO a wealth of experience with the unique regulatory and policy issues impacting biopharma companies and a comprehensive knowledge of the Food & Drug Administration (FDA). We are excited to have her join us to enhance BIO’s advocacy for a regulatory environment that allows the biotechnology industry to bring life-saving and life-enhancing technologies to market.”
Ms. Dennis was most recently a Partner at Morgan, Lewis, & Bockius, LLP, where she focused on the FDA/Healthcare Regulation practice, with a concentration on regulatory, legislative, policy and corporate/transactional aspects of food, drug, and medical device law. She also has a long history of working on women’s health issues.
“Sandi is a highly respected member of the FDA bar and we are fortunate to have her join our team,” said Tom DiLenge, BIO’s Vice President and General Counsel. “She’s worked with both large and small BIO member companies for more than two decades, and understands the complex mix of regulatory, scientific, and commercial issues involved in the research and development of biotechnology products. This experience, combined with her legislative and policy skills, will help advance BIO’s advocacy goals on behalf of our member companies.”
Previously, Ms. Dennis worked at the legal firms of Fox, Bennett & Turner, and Keller & Heckman as an Associate and Partner. Ms. Dennis also served as a local television news anchor in Columbia, South Carolina.
She holds a B.A. from the Pennsylvania State University, and received her J.D. from the University of South Carolina School of Law.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.
· BIO CEO & Investor Conference
Feb. 12-14, 2007
New York City
· 2007 World Congress on Industrial Biotechnology and Bioprocessing
· BIO International Convention
May 6-9, 2007